HYVET: landmark trial voted 2008 Trialof the Year by the ImpACT/Society for Clinical Trials and the American Heart Association
- Authors: - -
- Issue: Vol 6, No 2 (2009)
- Pages: 44-45
- Section: Articles
- URL: https://journals.eco-vector.com/2075-082X/article/view/28852
- DOI: https://doi.org/10.26442/SG28852
- ID: 28852
Cite item
Full Text
Abstract
References
- Beckett NS, Peters R, Fletcher AE et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358: 1887-98.
- United Nations. World population ageing 1950-2050. IV. Demographic profile of the older population. Available from http://www.un.org/esa/population/publications/worldageing19502050/pdf/90chapteriv.pdf.
- Leonetti G, Emeriau J-P, Knauf H et al. Evaluation of long-term efficacy and acceptability of indapamide SR in elderly hypertensive patients. Curr Med Res Opin 2005; 21: 37-46.
- Peters R, Beckett N, Forette F et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet 2008; 7: 683-9.
- American Heart Association. News release. Top research advances include studies that influence medical care, apply science to «real world» communities. January 21, 2009. Available from http://americanheart.mediaroom.com/index.php?s=43&item=648.
- Medscape Cardiology. This Year's Awards for the Most Important Trials Go to... HYVET and ACCOMPLISH. March 2, 2009. Available from http://cme.medscape.com/viewarticle/588818.
- Faculty of 1000 Medicine. All time Top 10 by F1000 factor. All of Medicine. March 30, 2009. Available from http://www.f1000medicine.com/top10/ classics/.
- Weidmann P. Metabolic profile of indapamide sustained-release in patients with hypertension. Drugs Safety 2001; 24: 1155-65.